» Articles » PMID: 28839937

Proteomic and Transcriptomic Analyses to Explain the Pleiotropic Effects of Ankaferd Blood Stopper

Overview
Journal SAGE Open Med
Publisher Sage Publications
Specialty General Medicine
Date 2017 Aug 26
PMID 28839937
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Ankaferd blood stopper is a standardized mixture of the plants , , , , and and has been used as a topical hemostatic agent and with its clinical application established in randomized controlled trials and case reports. Ankaferd has been successfully used in gastrointestinal endobronchial mucosal and cutaneous bleedings and also in abdominal, thoracic, dental and oropharyngeal, and pelvic surgeries. Ankaferd's hemostatic action is thought to form a protein complex with coagulation factors that facilitate adhesion of blood components. Besides its hemostatic action, Ankaferd has demonstrated pleiotropic effects, including anti-neoplastic and anti-microbial activities and tissue-healing properties; the underlying mechanisms for these have not been well studied. Ankaferd's individual components were determined by proteomic and chemical analyses. Ankaferd also augments transcription of some transcription factors which is shown with transcriptomic analysis. The independent effects of these ingredients and augmented transcription factors are not known precisely. Here, we review what is known of Ankaferd blood stopper components from chemical, proteomic, and transcriptomic analyses and propose that individual components can explain some pleiotropic effects of Ankaferd. Certainly more research is needed focusing on individual ingredients of Ankaferd to elucidate their precise and effects.

Citing Articles

Drug interaction potential of Ankaferd blood stopper® in human hepatocarcinoma cells.

Semiz A Turk J Med Sci. 2023; 53(2):455-462.

PMID: 37476879 PMC: 10388094. DOI: 10.55730/1300-0144.5605.


A review of the effects of (nettle) in metabolic syndrome.

Samakar B, Mehri S, Hosseinzadeh H Iran J Basic Med Sci. 2022; 25(5):543-553.

PMID: 35911652 PMC: 9282742. DOI: 10.22038/IJBMS.2022.58892.13079.


Comparison of hemostatic efficacy of topical Ankaferd Blood Stopper on heparinized and nonheparinized rats in bleeding related to liver injury.

Ergin M, Ozer N Acta Cir Bras. 2021; 36(1):e360106.

PMID: 33533829 PMC: 7853696. DOI: 10.1590/ACB360106.


Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach.

Kocak E, Celebier M, Haznedaroglu I, Altinoz S Biomed Res Int. 2019; 2019:5268031.

PMID: 31240215 PMC: 6556321. DOI: 10.1155/2019/5268031.


The efficacy of Ankaferd Blood Stopper in an experimental Asherman syndrome model created in rats.

Buyuk B, Beyazit F Turk J Obstet Gynecol. 2019; 16(1):7-14.

PMID: 31019834 PMC: 6463422. DOI: 10.4274/tjod.galenos.2018.21298.

References
1.
Kocak E, Akbal E, Tas A, Koklu S, Karaca G, Can M . Anti-inflammatory efficiency of Ankaferd blood stopper in experimental distal colitis model. Saudi J Gastroenterol. 2013; 19(3):126-30. PMC: 3709375. DOI: 10.4103/1319-3767.111955. View

2.
Ozaslan E, Purnak T, Yildiz A, Akar T, Avcioglu U, Haznedaroglu I . The effect of Ankaferd blood stopper on severe radiation colitis. Endoscopy. 2009; 41 Suppl 2:E321-2. DOI: 10.1055/s-0029-1215325. View

3.
Yilmaz E, Gulec S, Torun D, Haznedaroglu I, Akar N . The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. Turk J Haematol. 2016; 28(4):276-85. DOI: 10.5152/tjh.2011.39. View

4.
Sassa Y, Hata Y, Murata T, Yamanaka I, Honda M, Hisatomi T . Functional role of Egr-1 mediating VEGF-induced tissue factor expression in the retinal capillary endothelium. Graefes Arch Clin Exp Ophthalmol. 2002; 240(12):1003-10. DOI: 10.1007/s00417-002-0576-6. View

5.
Fisgin N, Cayci Y, Coban A, Ozatli D, Tanyel E, Durupinar B . Antimicrobial activity of plant extract Ankaferd Blood Stopper. Fitoterapia. 2008; 80(1):48-50. DOI: 10.1016/j.fitote.2008.09.006. View